iShares U.S. Pharmaceuticals ETF $IHE Stake Lifted by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC increased its stake in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 4.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,898 shares of the company’s stock after buying an additional 201 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in iShares U.S. Pharmaceuticals ETF were worth $321,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Raab & Moskowitz Asset Management LLC lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 4.4% in the first quarter. Raab & Moskowitz Asset Management LLC now owns 4,803 shares of the company’s stock valued at $339,000 after buying an additional 204 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 20.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the company’s stock valued at $90,000 after buying an additional 216 shares during the period. Truist Financial Corp lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 2.8% in the second quarter. Truist Financial Corp now owns 9,104 shares of the company’s stock valued at $593,000 after buying an additional 252 shares during the period. Institute for Wealth Management LLC. lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 2.6% in the first quarter. Institute for Wealth Management LLC. now owns 11,283 shares of the company’s stock valued at $796,000 after buying an additional 291 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 0.3% in the first quarter. Royal Bank of Canada now owns 101,984 shares of the company’s stock valued at $7,197,000 after buying an additional 325 shares during the period.

iShares U.S. Pharmaceuticals ETF Stock Up 0.5%

Shares of iShares U.S. Pharmaceuticals ETF stock opened at $75.58 on Friday. The firm has a market cap of $608.42 million, a price-to-earnings ratio of 17.75 and a beta of 0.70. The business has a fifty day simple moving average of $70.63 and a 200-day simple moving average of $67.45. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $58.97 and a fifty-two week high of $76.14.

iShares U.S. Pharmaceuticals ETF Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.